Velasof (Sofosbuvir/Velpatasvir) 400 mg / 100 mg
Velasof is a pan-genotypic fixed-dose combination aimed at curing Hepatitis C. Active ingredients: Sofosbuvir (400 mg) + Velpatasvir (100 mg).
Manufacturer: Hetero Healthcare (India). Generic equivalent of the blockbuster drug Epclusa.
The Universal Cure:
Velasof is designed to treat ALL genotypes (1 through 6) of the Hepatitis C virus. It simplifies treatment as it eliminates the absolute need for genotyping testing in resource-limited settings. It is particularly superior for treating the difficult Genotype 3.
✅ High Cure Rate: Achieves SVR12 (cure) in >95-99% of patients.
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adults:
- All Genotypes (1-6).
- Patients without cirrhosis or with compensated cirrhosis.
- Patients with decompensated cirrhosis (in combination with Ribavirin).
Standard Dosage: One tablet taken orally once daily for 12 weeks.
⚠️ CRITICAL INTERACTION (Antacids/PPIs):
Velpatasvir solubility decreases as pH increases. If you take antacids or Proton Pump Inhibitors (like Omeprazole):
- Take Velasof 4 hours BEFORE antacids.
- Take Velasof with food 4 hours before taking Omeprazole (maximum 20 mg).
🚫 CARDIAC WARNING: AMIODARONE.
Co-administration with Amiodarone may result in serious symptomatic bradycardia. This combination is contraindicated.
Other Contraindications:
- Pregnancy and breastfeeding.
- Strong P-gp inducers (Rifampin, St. John's Wort, Carbamazepine) – these reduce the efficacy of Velasof.
Side effects are typically mild and transient:
- Headache and Fatigue.
- Nausea.
- HBV Reactivation: Screening for Hepatitis B virus is mandatory before initiating treatment, as reactivation of dormant HBV can occur.
What Customers Say
No reviews yet
Your review can be the first!